Study of Oral Gil 47211 Bioavailability
Author Information
Author(s): CJH Gerrits, JHM Schellens, GJ Creemers, P Wissel, ASTh Planting, JF Pritchard, S DePee, M de Boer-Dennert, M Harteveld, J Verweij
Primary Institution: Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, The Netherlands
Hypothesis
The study aims to determine the absolute bioavailability of the drug Gil 47211 when administered orally.
Conclusion
Oral administration of the topoisomerase I inhibitor Gil 47211 results in low bioavailability with significant interpatient variation.
Supporting Evidence
- The absolute bioavailability of Gil 47211 averaged 11.3 ± 5.2%.
- Drug appeared quickly in plasma with a median Tmax of 0.5 h.
- Neutropenia and thrombocytopenia were the major toxicities observed.
- Oral administration of the drug is well tolerated.
- Fasting or fed state had no significant influence on the bioavailability.
Takeaway
The medicine Gil 47211 doesn't get absorbed well when taken by mouth, so it's better to give it through an injection.
Methodology
Patients with solid tumors received Gil 47211 orally and intravenously, with pharmacokinetics assessed through blood samples.
Limitations
The study had a small sample size and variability in drug absorption among patients.
Participant Demographics
{"total_patients":19,"sex_ratio":"7 males, 12 females","median_age":55,"age_range":"21-67"}
Want to read the original?
Access the complete publication on the publisher's website